Clinical Trial Update: The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of intravitreal aflibercept for persistent Central Serous Chorioretinopathy; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Wills Eye | Conditions: Central Serous Chorioretinopathy | Phase 2 | Status: COMPLETED | Results posted: 2017-04-07